Regulators of mitosis have been successfully targeted to enhance response to taxane chemotherapy. Here, we show that the salt inducible kinase 2 (SIK2) localizes at the centrosome, plays a key role in the initiation of mitosis, and regulates the localization of the centrosome linker protein, C-Nap1, through S2392 phosphorylation. Interference with the known SIK2 inhibitor PKA induced SIK2-dependent centrosome splitting in interphase while SIK2 depletion blocked centrosome separation in mitosis, sensitizing ovarian cancers to paclitaxel in culture and in xenografts. Depletion of SIK2 also delayed G1/S transition and reduced AKT phosphorylation. Higher expression of SIK2 significantly correlated with poor survival in patients with high-grade serous ovarian cancers. We believe these data identify SIK2 as a plausible target for therapy in ovarian cancers.
Highlights
► A kinome screen identifies SIK2 as a centrosome kinase required for mitosis ► SIK2 phosphorylates C-Nap1 and is required for centrosome separation in mitosis ► Targeted SIK2 depletion results in synergy with taxanes in ovarian cancers ► Depletion of SIK2 results in delayed G1/S transition and low AKT phosphorylation
Present address: The Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Level 3, Women's Centre, Oxford OX3 9DU, UK
